Chemotherapy in Treating Children With Liver Cancer - Full Text View

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective in treating children with liver cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of cisplatin with or without doxorubicin and the effectiveness of combining cisplatin, carboplatin, and doxorubicin in treating children who have liver cancer.

Condition	Intervention	Phase
Liver Cancer	Drug: carboplatin Drug: cisplatin Drug: doxorubicin hydrochloride Procedure: conventional surgery	Phase III

MedlinePlus related topics:

Cancer Liver Cancer

Drug Information available for:

Doxorubicin Doxorubicin hydrochloride Carboplatin Cisplatin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Active Control

Official Title:	Liver Tumour Studies - Hepatoblastoma and Hepatocellular Carcinoma

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Tumor response [ Designated as safety issue: No ]
Complete resection rate [ Designated as safety issue: No ]
Overall survival [ Designated as safety issue: No ]
Event-free survival [ Designated as safety issue: No ]
Toxicity [ Designated as safety issue: Yes ]
Response rate [ Designated as safety issue: No ]
Resection rate [ Designated as safety issue: No ]

Estimated Enrollment:	260
Study Start Date:	June 1998

Show Detailed Description

Eligibility

Ages Eligible for Study:	up to 16 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically proven hepatoblastoma or hepatocellular carcinoma
- Diagnostic surgical biopsy strongly recommended for all patients and mandatory for the following:
  - Children under 6 months of age
  - Children over 3 years of age
  - Patients with a normal serum alfa-fetoprotein (alfa-FP)
- Compatible imaging and raised serum alfa-FP level mandatory if no biopsy performed
Standard risk disease:
- Tumors involving no more than 3 hepatic sections
- No extrahepatic abdominal disease
- No metastases
High risk disease:
- Tumors involving all 4 hepatic sections AND/OR
- Evidence of extrahepatic metastases or abdominal disease
Presence or absence of metastatic disease must be documented by chest x-ray and/or lung CT scan

PATIENT CHARACTERISTICS:

Age:

16 and under at diagnosis

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

Not specified

Radiotherapy:

Not specified

Surgery:

See Disease Characteristics
Prior surgery allowed

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003912

Locations


Italy
	Azienda Ospedaliera di Padova
	Padova, Italy, 35128

Sponsors and Collaborators

Societe Internationale d'Oncologie Pediatrique

Investigators


Study Chair:	Giorgio Perilongo, MD	Azienda Ospedaliera di Padova

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications:

Brock P, Shafford E, Brugieres L, et al.: Metastatic hepatoblastoma (HB) treated with a dose intensive multiagent chemotherapy regimen, results from the second study of the Childhood Liver Tumour Strategy Group of the International Society of Pediatric Oncology- SIOPEL 2. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1603, 2002.

Perilongo G, Shafford E, Brugieres L, et al.: Cisplatin (CDDP) alone and delayed surgery, an effective treatment for standard risk (SR) hepatoblastoma (HB), the most relevant finding of the SIOPEL2. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1571, 2002.

Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol. 2000 Oct;1:94-100. Review.

Study ID Numbers:	CDR0000067091, SIOP-SIOPEL-3, EU-98067, UKCCSG-LT-1998-01
First Received:	November 1, 1999
Last Updated:	May 23, 2008
ClinicalTrials.gov Identifier:	NCT00003912
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

stage I childhood liver cancer

stage II childhood liver cancer

stage III childhood liver cancer

stage IV childhood liver cancer

recurrent childhood liver cancer

childhood hepatoblastoma

childhood hepatocellular carcinoma

Study placed in the following topic categories:

Liver Diseases

Digestive System Neoplasms

Carcinoma, Hepatocellular

Liver neoplasms

Carboplatin

Doxorubicin

Recurrence

Carcinoma

Liver Neoplasms

Digestive System Diseases

Cisplatin

Gastrointestinal Neoplasms

Hepatoblastoma

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Hepatocellular carcinoma

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

Neoplasms by Histologic Type

Antineoplastic Agents

Therapeutic Uses

Antibiotics, Antineoplastic

Pharmacologic Actions

Neoplasms, Complex and Mixed

ClinicalTrials.gov processed this record on November 20, 2008

Sponsored by:	Societe Internationale d'Oncologie Pediatrique
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00003912